Wedbush Analysts Boost Earnings Estimates for PepGen

PepGen Inc. (NASDAQ:PEPG) – Investment analysts at Wedbush boosted their Q1 2025 earnings estimates for shares of PepGen in a research note issued to investors on Monday, February 24th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.54) for the quarter, up from their previous forecast of ($0.65). Wedbush currently has a “Outperform” rating and a $12.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen’s Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.22) EPS, FY2026 earnings at ($2.11) EPS, FY2027 earnings at ($1.91) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.10) EPS.

A number of other equities research analysts have also commented on the company. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research report on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of PepGen in a research note on Monday.

PepGen Stock Performance

Shares of PEPG opened at $1.53 on Thursday. The stock has a 50-day moving average of $2.41 and a two-hundred day moving average of $5.75. The stock has a market cap of $49.87 million, a P/E ratio of -0.51 and a beta of 1.53. PepGen has a one year low of $1.16 and a one year high of $19.30.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13.

Hedge Funds Weigh In On PepGen

Institutional investors have recently modified their holdings of the stock. RTW Investments LP acquired a new stake in PepGen during the fourth quarter worth about $12,102,000. Millennium Management LLC boosted its position in PepGen by 1,033.2% in the 4th quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock worth $594,000 after purchasing an additional 142,814 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in PepGen in the 4th quarter worth approximately $516,000. Deutsche Bank AG grew its stake in shares of PepGen by 442.5% during the 4th quarter. Deutsche Bank AG now owns 44,735 shares of the company’s stock worth $170,000 after purchasing an additional 36,489 shares during the period. Finally, Corton Capital Inc. purchased a new position in shares of PepGen during the 4th quarter valued at approximately $68,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.